Condition or disease | Intervention/treatment | Phase |
---|---|---|
ANCA Associated Vasculitis Granulomatosis With Polyangiitis | Drug: Belimumab Drug: Rituximab Drug: Prednisolone | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis |
Actual Study Start Date : | February 1, 2019 |
Estimated Primary Completion Date : | February 2023 |
Estimated Study Completion Date : | February 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Belimumab
Weekly 200mg SC injections of belimumab for 12 months
|
Drug: Belimumab
Sub-cutaneous injection
Other Name: Benlysta
Drug: Rituximab IV infusion 1g x 2
Other Name: Truxima
Drug: Prednisolone 20mg prednisolone tapering dose
Other Name: prednisone
|
Placebo Comparator: Belimumab placebo
Weekly SC injections of belimumab placebo for 12 months
|
Drug: Rituximab
IV infusion 1g x 2
Other Name: Truxima
Drug: Prednisolone 20mg prednisolone tapering dose
Other Name: prednisone
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Participants must be 18 of age
Exclusion Criteria:
United Kingdom | |
Addenbrooke's Hospital | Recruiting |
Cambridge, United Kingdom | |
Contact: Kim Mynard 01223 349350 kim.mynard@addenbrookes.nhs.uk | |
Principal Investigator: Rachel Jones | |
Glasgow Royal Infirmary | Active, not recruiting |
Glasgow, United Kingdom | |
Imperial College London | Active, not recruiting |
London, United Kingdom | |
Royal Free Hospital | Active, not recruiting |
London, United Kingdom | |
Royal Freemann Hospital | Active, not recruiting |
Newcastle, United Kingdom | |
Nottingham University Hospitals | Active, not recruiting |
Nottingham, United Kingdom |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | January 18, 2019 | ||||
First Posted Date ICMJE | May 30, 2019 | ||||
Last Update Posted Date | July 9, 2020 | ||||
Actual Study Start Date ICMJE | February 1, 2019 | ||||
Estimated Primary Completion Date | February 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Time to PR3 ANCA negativity [ Time Frame: Analysed at 24 months ] ELISA analysis at different time points to determine when PR3 ANCA can no longer be detected
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | ||||
Official Title ICMJE | A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis | ||||
Brief Summary | Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and clinical status compared to rituximab with placebo. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
30 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | February 2023 | ||||
Estimated Primary Completion Date | February 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria: Participants must be 18 of age
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | |||||
Listed Location Countries ICMJE | United Kingdom | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03967925 | ||||
Other Study ID Numbers ICMJE | 206852 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Rachel Jones, Cambridge University Hospitals NHS Foundation Trust | ||||
Study Sponsor ICMJE | Rachel Jones | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE | Not Provided | ||||
PRS Account | Cambridge University Hospitals NHS Foundation Trust | ||||
Verification Date | July 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |